Tissue Regenix

What they do

Tissue Regenix Group manufactures and distributes regenerative medical products built around two proprietary platform technologies: dCELL® and BioRinse™. The dCELL® platform is a decellularisation process — it strips donor tissue of cells while preserving the structural scaffold, allowing the patient's own cells to repopulate it. BioRinse™ is a complementary platform focused on bone and soft tissue processing. Together, they underpin a portfolio of allografts (human-derived) and xenografts (animal-derived) aimed at improving patient outcomes in orthopaedics and related clinical areas.

The company runs two manufacturing and distribution sites. The Leeds facility is the corporate headquarters and handles porcine tissue medical device manufacturing, including the OrthoPure® XT Ligament Reconstruction Implant. It is certified to ISO 13485:2016. The San Antonio, Texas site — formerly operating as CellRight Technologies — processes, stores and distributes Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P) to hospitals, medical professionals and approved distribution partners across the US. That facility is AATB-accredited and registered with the FDA, operating in compliance with FDA regulations, AATB Standards and relevant state requirements.

The regenerative medicine field that Tissue Regenix works in is built on the idea that processed biological scaffolds can trigger the body's own repair mechanisms, rather than relying on synthetic implants or long-term immunosuppression. Decellularisation is central to this: by removing the donor cells that would otherwise provoke an immune response, the remaining extracellular matrix can act as a template for the recipient's tissue to grow into.

The Leeds site also serves as the group's R&D hub, with the University of Leeds connection providing access to academic research capability. The company describes this relationship as ongoing, with future portfolio developments in the pipeline, though specifics are not disclosed publicly.

Where they sit in Leeds

Tissue Regenix is one of the more established medtech businesses to have grown out of the University of Leeds ecosystem. The university has a long track record in biomaterials and tissue engineering research, and Tissue Regenix represents a direct commercialisation of that work. Their Leeds base keeps the R&D function close to that academic source while the San Antonio operation handles the scale and regulatory requirements of the US market.

For the Leeds tech and life sciences community, Tissue Regenix sits at the intersection of manufacturing, regulatory science and biomedical research. The ISO 13485:2016 certification at the Leeds site reflects the quality management demands of medical device production — a different discipline from software-led tech, but one that requires significant engineering and scientific rigour. The OrthoPure® XT implant, manufactured in Leeds and used in ligament reconstruction, is a concrete example of that work reaching patients.

The company describes itself as international in scope, with products reaching hospitals and medical professionals through approved distribution channels in multiple markets. The dual-site structure — UK corporate and R&D, US processing and distribution — reflects both the regulatory geography of medical devices and the commercial weight of the American healthcare market.

What they offer

• dCELL® platform — proprietary decellularisation technology applied to soft tissue, removing donor cells to create a biological scaffold for patient tissue regeneration.
• BioRinse™ platform — complementary bone and soft tissue processing technology, used alongside dCELL® across the product portfolio.
• OrthoPure® XT Ligament Reconstruction Implant — a porcine-derived xenograft manufactured at the Leeds facility, used in ligament reconstruction procedures.
• Allograft and xenograft products — processed human and animal tissue products distributed to hospitals and medical professionals via the San Antonio facility and approved distribution partners.